Evidence map›Paper›PMID 37940678›Full record

Observational studyScientific reports2023

Prophylactic treatment can modify vascular risk biomarkers in high-frequency episodic and chronic migraine patients: a pilot study.

Cristina González Mingot, Sonia Santos Lasaosa, Laura Colàs Campàs, Laura Chilangua Canaval, Anna Gil Sánchez, Luis Brieva Ruiz, María Cristina Marzo Alonso, Silvia Peralta Moncusi, Joan Valls Marsal, Serafí Cambray Carner and 1 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Cristina González MingotNeuroimmunology Group, Department of Medicine, University of Lleida (UdL)-IRBLleida, Alcalde Rovira Roure 80, 25198, Lleida, Spain. cristina.gonzalez@udl.cat.ORCID 0000-0002-6387-8764
Sonia Santos LasaosaNeurology Service of Hospital Clínico Lozano Blesa of Zaragoza, Zaragoza, Spain.ORCID 0000-0002-4141-7705
Laura Colàs CampàsBiomedical Research Institute of Lleida, Lleida, Spain.ORCID 0000-0002-0544-4044
Laura Chilangua CanavalNeurology Service of Hospital Son Espases, Palma, Illes Balears, Spain.ORCID 0000-0002-7785-494X
Anna Gil SánchezNeuroimmunology Group, Department of Medicine, University of Lleida (UdL)-IRBLleida, Alcalde Rovira Roure 80, 25198, Lleida, Spain.ORCID 0000-0002-0738-5578
Luis Brieva RuizNeuroimmunology Group, Department of Medicine, University of Lleida (UdL)-IRBLleida, Alcalde Rovira Roure 80, 25198, Lleida, Spain.ORCID 0000-0002-5871-6189
María Cristina Marzo AlonsoHematology Service of Hospital Arnau de Vilanova of Lleida, Lleida, Spain.ORCID 0000-0001-6085-2158
Silvia Peralta MoncusiNeuroimmunology Group, Department of Medicine, University of Lleida (UdL)-IRBLleida, Alcalde Rovira Roure 80, 25198, Lleida, Spain.ORCID 0000-0002-9537-4587
Joan Valls MarsalBiomedical Research Institute of Lleida, Lleida, Spain.ORCID 0000-0002-4806-7568
Serafí Cambray CarnerBiomedical Research Institute of Lleida, Lleida, Spain.ORCID 0000-0002-3831-3884
Francisco Purroy GarcíaNeurology Service of Hospital Arnau de Vilanova of Lleida, Lleida, Spain.ORCID 0000-0002-1808-5968
Universitat de Lleida · ESInstituto de Investigación Biomédica de Lleida · ESHospital Arnau de Vilanova · ESHospital Clínico Universitario Lozano Blesa · ESHospital Universitario Son Espases · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate whether preventive treatment can modify endothelial and oxidative biomarkers of vascular disease risk in patients with high-frequency episodic and chronic migraine. In this observational, prospective pilot study, 88 prophylactic treatment-naïve patients with episodic and chronic migraine and 56 healthy sex/age matched controls underwent ultrasonography exams and blood tests at baseline, and again in the migraine patients after 3 months' treatment with metoprolol or topiramate. Biomarkers for endothelial function and oxidative stress were analyzed. At baseline, patients with migraine in the low-frequency episodic group had differences exclusively in nitrates 17.6 versus 27.33 µM; p = 0.046 compared to the controls. However, when comparing the group comprised of patients with high-frequency episodic migraine and chronic migraine versus controls, statistically significant differences appeared in hsCRP 2.68 versus 1.64 mg/dL; p = 0.049, vWF antigen (133% vs. 110%; p = 0.020, vWF activity (111% vs. 90%; p = 0.010) and isoprostane levels (181 vs. 238 µM; p = 0.05). Only in the chronic migraine subgroup did we found statistically significant differences in CIMT (0.60 vs. 0.54 mm; p = 0.042) which were significantly greater than in the controls. After treatment, patients who respond to preventive treatment exhibited significantly higher levels of nitrates (24.2-13.8 µM; p = 0.022) and nitrites (10.4-3.43 µM; p = 0.002) compared than non-responders. Moreover, biomarker levels improved in treatment-responsive patients with migraine; hsCRP levels decreased from 2.54 to 1.69 mg/dL (p < 0.05), vWF activity levels decreased from 124 to 103 IU/dL (p = 0.003) and prothrombin activity decreased from 1.01 to 0.93 (p = 0.01). These differences were also observed in the high-frequency and chronic migraine subgroup and reach statistical significance in the case of hsCRP, which decreased from 2.12 to 0.83 mg/dL (p = 0.048). Patients with migraines have differences in biomarker levels compared to controls, suggesting endothelial and oxidative dysfunction. The greatest differences in biomarker levels compared to controls are observed in migraine patients in the high-frequency and chronic migraine subgroups. Based on our results, preventive treatment is capable of modifying markers of endothelial dysfunction and oxidative stress in migraine patients, even in cases of chronic and high-frequency migraine.

Indexed as

Migraine DisordersVascular DiseasesBiomarkersC-Reactive ProteinHumansInfantPilot ProjectsProspective Studiesvon Willebrand FactorBiomarkersC-Reactive Proteinvon Willebrand Factor

Identifiers

PMID37940678
PMCPMC10632400
OpenAlexW4388488737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.